After CEO-switching saga CureVac names full-time chief, CSO

Franz-Werner Haas, interim CEO of CureVac
CureVac CEO Franz-Werner Haas (CureVac)

Even as it scrambled to pitch in against the COVID-19 pandemic, CureVac found itself embroiled in a game of executive musical chairs, losing two CEOs in as many weeks. Now, as it pushes an mRNA vaccine toward the clinic, it’s named a permanent chief, Franz-Werner Haas, and signed a Novartis alum, Igor Splawski, Ph.D. as its new top scientist.

Haas has led the company as interim CEO and chief operating officer since March, the same month that Daniel Menichella, CureVac’s CEO since 2018, mysteriously departed. Menichella’s replacement was, in fact, the man he replaced two years earlier: Ingmar Hoerr, CureVac’s founding CEO.

Hoerr’s second tour as chief executive didn’t last, though—a week later, the company announced he would take a temporary leave of absence for medical (but not COVID-19-related) reasons. At the time, CureVac said that Haas would take over Hoerr’s role “until his return.” Now, Haas is taking “interim” off his job title.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

RELATED: Was it something he said? Biotech CEO who met Trump this month exits without a word

He’s joined by Splawski, who arrives at CureVac after running a biologics center for Novartis Institutes for Biomedical Research. As chief scientific officer, Splawski will lead the company’s mRNA biology research, including work on its closely watched mRNA COVID-19 vaccine.

The biotech is much further back than its mRNA rivals Moderna and BioNTech/Pfizer, who are all working on late-stage efforts, but given that the pandemic will likely need as many vaccines as possible, and with safety/efficacy keenly watched, it will still have a potentially big role in the R&D effort.

RELATED: GSK hands CureVac $294M to form mRNA infectious disease pact

The executive changes come two weeks after CureVac closed a $640 million private round from players like the German federal government, GlaxoSmithKline and Qatar Investment Authority. The haul was larger than all of CureVac’s previously disclosed financings combined and arrived before the company published data on how its COVID-19 vaccine, CVnCoV, works in humans. Belgian and German authorities cleared CureVac to start a phase 1 study of the vaccine in June.

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.